Products
Vopikitug Biosimilar Monoclonal Antibody (CD25) for Research
Cat No.: GMP-Bios-INN-1466
Anti-IL2RA/CD25 therapeutic antibody (Pre-made Vopikitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vopikitug (development codes RG 6292/RG6962) is a monoclonal antibody targeting IL-2 receptor alpha (IL2RA). It is developed by Roche for Acute myeloid leukaemia in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1466-1mg | 1mg | 3090 |
| GMP-Bios-INN-1466-10mg | 10mg | |
| GMP-Bios-INN-1466-100mg | 100mg | |
| GMP-Bios-INN-1466-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vopikitug biosimilar, Whole mAb, Anti-IL2RA/CD25 Antibody: Anti-CD25/IL-2RA/IL2RA/Interleukin-2 receptor subunit alpha therapeutic antibody |
| INN Name | Vopikitug |
| Target | IL2RA/CD25 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | 6yio:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | Acute myeloid leukaemia |
| Conditions Discontinued | Solid tumours |
| Production | na |
| Development Tech | na |
